Fool Poll: Which Blue Chip Will Turn Your Portfolio Green?

Recs

3

Disney Buys Marvel!

...And David Gardner called it. He's up 1,334%! See what David's recommending that you buy NEXT!

Click here now to find out!

In crazy market times such as these, investors often turn to defensive stocks -- big blue chips that should do well when the economy or the market slips. Here are three very popular ones from CAPS for your consideration:

Altria (NYSE: MO)
For a long time Altria was the ultimate "sin" stock, selling cigarettes the world over. In recent years it's trimmed itself back, having spun off the international cigarette franchise into Philip Morris International (NYSE: PM) early this year. It still holds its domestic cigarette business and is planning to add smokeless tobacco via an acquisition of UST (NYSE: UST), though that might be delayed a bit thanks to the current tight credit market. A forward dividend yield of 6.9%, backed by more than $1 billion in free cash flow over the first half of the year, help make the waiting until that happens easier. It carries a best-of-class five-star rating, with 96% of the nearly 7,000 calls going outperform.

General Electric (NYSE: GE)
GE is the conglomerates' conglomerate. Products range from light bulbs to aircraft engines, appliances to television networks. It's even into finance and energy. A 6% dividend yield should be more than safe, with more than $28 billion in trailing free cash flow. A return on equity of more than 18% is matched only by a net margin of 12% -- incredible when you look at the size of the company. Competitor United Technologies (NYSE: UTX) sports a worse net margin of 8%, but a better return on equity of 22%. In CAPS, 93% of the more than 10,400 ratings call for this company to outperform the market.

Johnson & Johnson (NYSE: JNJ)
J&J is a pharmaceutical powerhouse selling drugs to treat a wide range of illnesses, just like Pfizer (NYSE: PFE) does, but it's bolstered by a huge consumer products business supplying Band-Aid bandages, Tylenol, and other products to millions of people. Not only that, but it competes in the medical device space, with stents, joints, and implants, among others. These three sections drove more than $63 billion in revenue over the past four quarters, giving up more than $4 in earnings per share -- an 18% net margin. With net debt of only $868 million, trailing free cash flow of more than $11 billion, and a dividend yield of 3%, this company isn't in danger of implosion like some we could name. CAPS members give it a full five-star rating, with 99% of the nearly 9,500 ratings positive.

There's some information for you about three popular blue-chip companies. So which would be best for your portfolio during these hectic times and beyond?

On Oct. 7, 2008, Fool co-founder David Gardner and his Motley Fool Pro team invested $1 million in a portfolio designed to help you make money in any market. In the coming weeks, the team, relying heavily on proprietary CAPS "community intelligence" data, will establish long and short positions in a broad range of securities, including common stocks, publicly traded put and call options, and exchange-traded funds. To learn more about Motley Fool Pro and to receive a private invitation to join, simply enter your email address in the box below.

Take the Motley Poll

The blue chip I would invest in today is:

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

Jim Mueller is the CAPS sector editor for The Motley Fool. Of the companies mentioned, he's a beneficial owner of GE and owns shares of Johnson & Johnson, but he doesn't own any of the others. Both J&J and Pfizer are Income Investor picks, while Pfizer also shows up on Inside Value's list. The Fool owns some of Pfizer, too. The Fool's disclosure policy would answer "all three" if that was a choice.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 749491, ~/Articles/ArticleHandler.aspx, 11/9/2009 2:39:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Warren Buffett's Biggest Weakness

Related Tickers

11/9/2009 2:22 PM
GE $15.88 Up +0.55 +3.59%
General Electric C… CAPS Rating: ****
JNJ $60.60 Up +0.30 +0.50%
Johnson & Johnson CAPS Rating: *****
MO $18.89 Up +0.35 +1.89%
Altria Group, Inc. CAPS Rating: ****
PFE $17.35 Up +0.39 +2.30%
Pfizer, Inc. CAPS Rating: ****
UST $69.46 Down +0.00 +0.00%
UST, Inc. CAPS Rating: ***
UTX $66.49 Up +1.42 +2.18%
United Technologie… CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Charlie Munger: Charlie Munger is best known as the Vice Chairman, and Warren Buffett's second in command, at Berkshire Hathaway. He is also the CEO of Wesco. Munger, a graduate of Harvard Law School, was practicing law in Omaha, Nebraska when he met Warren Buffett, who would eventually convince him to change careers.

Want to learn more or edit this definition?
Click here to read more!